Translational COVID-19 vaccine. Safe and efficacious SARS-CoV-2-targeted vaccine

Helena Florindo

  • PROJECT LEADER

    Helena Florindo

  • HOST ORGANIZATION,
    COUNTRY

    Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal

  • DESCRIPTION

    Currently, there are no specific therapies for COVID-19. The long, asymptomatic incubation period of SARS-CoV-2 has resulted in rapid mass infection across the globe. Vaccines are now crucial to alleviate the present situation.

    We are developing a reproducible, biodegradable and safe nano-vaccine rationally designed for concomitant delivery of SARS-CoV-2 epitopes and regulators of immune cell function to generate protective anti-SARS-CoV-2 host responses.

    Our extensive previous data on cancer and preliminary findings using SARS-CoV-2 peptides validate our hypothesis that our unique nano-vaccine will upregulate dentritic cell activation/expansion, cytokine release and thereby induce T and B cell immunity.

  • MORE INFORMATION

    https://impulse.caixaresearch.org/en-US/web/guest/projects/-/caixaresearch/project/290282